Notice of Annual General Meeting/Proxy Form
Released
Released
Announcement PDF
Paradigm Biopharmaceuticals Ltd | ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
ASX RELEASE 20 October 2025
Dear Shareholders
2025 ANNUAL GENERAL MEETING
The Company’s annual general meeting is scheduled to be held at the offices of FB Rice, Level 33,
477 Collins Street, Melbourne VIC 3000, and as a virtual meeting on Wednesday, 19th November
2025 at 11:00am (AEDT) (Meeting), with registration from 10.30am (AEDT).
In accordance with new provisions under the Corporations Act, the Company will not be sending
hard copies of the Notice of Meeting to shareholders unless a shareholder has previously
requested a hard copy. The Notice of Meeting can be viewed and downloaded from
https://paradigmbiopharma.com/performance-progress/ Please also refer to the Online
Meeting Guide attached to the Notice of Meeting for details on how to participate in the
Meeting.
The Company strongly encourages Shareholders to lodge a directed proxy form prior to the
meeting. Questions should also be submitted in advance of the Meeting as this will provide
management with the best opportunity to prepare for the Meeting, for example by preparing
answers in advance to Shareholders questions. However, votes and questions may also be
submitted during the Meeting. Further details of how to participate in the Meeting are set out in
the Online Meeting Guide.
Please find below links to important Meeting documents:
Notice of Meeting and Explanatory Memorandum:
https://paradigmbiopharma.com/performance-progress/
Online Meeting platform:
https://www.automicgroup.com.au/virtual-agms/
Alternatively, a complete copy of the important Meeting documents has been posted on the
Company’s ASX market announcements page.
If you have nominated an email address and have elected to receive electronic communications
from the Company, you will also receive an email to your nominated email address with a link to
an electronic copy of the important Meeting documents.
In order to receive electronic communications from the Company in the future, please update
your Shareholder details online at www.investor.automic.com.au/#/home and log in with your
unique shareholder identification number and postcode (or country for overseas residents),
where you can find on your enclosed personalised proxy form. Once logged in you can also lodge
your proxy vote online by clicking on the “Vote” tab.
If you are unable to access any of the important Meeting documents online, please contact the
Company Secretary, Abby Macnish Niven, on +61 8 6382 1805 or via email at
amacnish@paradigmbiopharma.com
The Company will notify Shareholders via the Company’s website at
https://paradigmbiopharma.com and the Company’s ASX Announcement Platform at asx.com.au
(ASX:PAR) if changing circumstances impact the planning or arrangements for the Meeting.
This announcement is authorised for market release by the Board of Paradigm
Biopharmaceuticals Limited.
Sincerely,
Abby Macnish Niven
Company Secretary
PARADIGM BIOPHARMACEUTICALS LTD
ACN 169 346 963
NOTICE OF ANNUAL GENERAL MEETING
Notice is given that the Meeting will be held at:
TIME: 11:00am (AEDT)
DATE: 19 November 2025
PLACE: The offices of FB Rice
Level 33, 477 Collins Street
Melbourne VIC 3000.
The business of the Meeting affects your shareholding and your vote is important.
This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote,
they should seek advice from their professional advisers prior to voting.
The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001
(Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at
7:00pm (AEDT) on 17 November 2025.
1
B U S I N E S S O F T H E M E E T I N G
AGENDA
1. FINANCIAL STATEMENTS AND REPORTS
To receive and consider the annual financial report of the Company for the financial year
ended 30 June 2025 together with the declaration of the Directors, the Director’s report,
the Remuneration Report and the auditor’s report.
2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT
To consider and, if thought fit, to pass, with or without amendment, the following resolution
as a non-binding resolution:
“That, for the purposes of section 250R(2) of the Corporations Act and for all other
purposes, approval is given for the adoption of the Remuneration Report as
contained in the Company’s annual financial report for the financial year ended 30
June 2025.”
Note: the vote on this Resolution is advisory only and does not bind the Directors or the Company.
3. RESOLUTION 2 – RE-ELECTION OF A DIRECTOR – AMOS MELTZER
To consider and, if thought fit, to pass, with or without amendment, the following resolution
as an ordinary resolution:
“That, for the purpose of clause 13.3 of the Constitution, Listing Rule 14.5 and for all
other purposes, Amos Meltzer, a Director, retires by rotation, and being eligible, is re-
elected as a Director.”
4. RESOLUTION 3 – APPROVAL TO ISSUE TRANCHE 3 CONVERTIBLE NOTES TO OBSIDIAN GLOBAL
GP, LLC
To consider and, if thought fit, to pass, with or without amendment, the following resolution
as an ordinary resolution:
“That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given
for the Company to issue 5,000,000 Convertible Notes to Obsidian Global GP, LLC
(or its nominees), with the subsequent entitlement to convert into Shares (on the basis
described in the Explanatory Statement) on the terms and conditions set out in the
Explanatory Statement.”
5. RESOLUTION 4 – ISSUE OF PERFORMANCE RIGHTS TO PAUL RENNIE
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is
given for the Company to issue 1,500,000 Performance Rights to Paul Rennie (or his
nominee) under the Paradigm Employee Performance Rights Plan (as approved by
shareholders at the 2023 AGM) on the terms and conditions set out in the
Explanatory Statement.”
A voting exclusion statement and voting prohibition statement applies to this Resolution. Please see below.
6. RESOLUTION 5 – APPROVAL OF 7.1A MANDATE
To consider and, if thought fit, to pass the following resolution as a special resolution:
“That, for the purposes of Listing Rule 7.1A and for all other purposes, approval is
given for the Company to issue up to that number of Equity Securities equal to 10%
of the issued capital of the Company at the time of issue, calculated in accordance
with the formula prescribed in Listing Rule 7.1A.2 and otherwise on the terms and
conditions set out in the Explanatory Statement.”
2
7. RESOLUTION 6 – RENEWAL OF PROPORTIONAL TAKEOVER PROVISIONS IN THE CONSTITUTION
To consider and, if thought fit, to pass the following resolution as a special resolution:
“That, for the purposes of sections 136(2) and 648G of the Corporations Act and for
all other purposes, approval is given for the Company to modify its existing
Constitution by renewing clause 11 for a period of three years from the date of
approval of this Resolution.”
Dated: 20 October 2025
3
Voting Prohibition Statements
Resolution 1 – Adoption of
Remuneration Report
In accordance with sections 250(BD)(2) and 250R, a vote on this Resolution must
not be cast:
(a) by or on behalf of a member of the Key Management Personnel,
details of whose remuneration are included in the Remuneration
Report or a Closely Related Party of such a member, regardless of the
capacity in which the vote is cast; or
(b) as a proxy by a member of the Key Management Personnel at the
date of the Meeting, or their Closely Related Parties.
However, a person (the voter) described above may cast a vote on this
Resolution as a proxy if the vote is not cast on behalf of a person described
above and either:
(a) the voter is appointed as a proxy by writing that specifies the way the
proxy is to vote on this Resolution; or
(b) the voter is the Chair and the appointment of the Chair as proxy:
(i) does not specify the way the proxy is to vote on this
Resolution; and
(ii) expressly authorises the Chair to exercise the proxy even
though this Resolution is connected directly or indirectly
with the remuneration of a member of the Key
Management Personnel.
Resolution 4 – Issue of
Performance Rights to Paul
Rennie
A person appointed as a proxy must not vote, on the basis of that appointment,
on this Resolution if:
(a) the proxy is either:
(i) a member of the Key Management Personnel; or
(ii) a Closely Related Party of such a member; and
(b) the appointment does not specify the way the proxy is to vote on this
Resolution.
However, the above prohibition does not apply if:
(a) the proxy is the Chair; and
(b) the appointment expressly authorises the Chair to exercise the proxy
even though this Resolution is connected directly or indirectly with
remuneration of a member of the Key Management Personnel.
Voting Exclusion Statements
In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the
Resolution set out below by or on behalf of the following persons:
Resolution 3 – Approval to issue
Tranche 3 Convertible Notes to
Obsidian Global GP, LLC
Obsidian Global GP, LLC (or its nominee/s) or any other person who is expected
to participate in, or who will obtain a material benefit as a result of, the proposed
issue (except a benefit solely by reason of being a holder of ordinary securities in
the Company) or an associate of that person (or those persons).
Resolution 4 – Issue of
Performance Rights to Paul
Rennie
Any person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to
participate in the employee incentive scheme in question (including Paul
Rennie) or an associate of that person or those persons.
However, this does not apply to a vote cast in favour of the Resolution by:
(a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in
accordance with the directions given to the proxy or attorney to vote on the Resolution in
that way; or
(b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in
accordance with a direction given to the Chair to vote on the Resolution as the Chair
decides; or
(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf
of a beneficiary provided the following conditions are met:
(i) the beneficiary provides written confirmation to the holder that the beneficiary is
not excluded from voting, and is not an associate of a person excluded from
voting, on the Resolution; and
(ii) the holder votes on the Resolution in accordance with directions given by the
beneficiary to the holder to vote in that way.
4
Venue and Voting Information
The company is pleased to provide shareholders with the opportunity to attend and participate in
a virtual Meeting through an online meeting platform powered by Automic.
Shareholders that have an existing account with Automic will be able to watch, listen and vote
online.
Shareholders who do not have an account with Automic are strongly encouraged to register for an
account as soon as possible and well in advance of the Meeting to avoid any delays on the day of
the Meeting.
An account can be created via the following link investor.automic.com.au and then clicking on
“register” and following the prompts. Shareholders will require their holder number (Securityholder
Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic.
To access the virtual meeting on the day:
1. Open your internet browser and go to investor.automic.com.au
2. Login with your username and password or click “register” if you haven’t already created
an account. Shareholders are encouraged to create an account prior to the start of the
meeting to ensure there is no delay in attending the virtual meeting.
3. After logging in, a banner will display at the bottom of your screen to indicate that the
meeting is open for registration, click on “Register” when this appears. Alternatively, click on
“Meetings” on the left-hand menu bar to join the meeting.
4. Click on “Join Meeting” and follow the prompts on screen to register and vote.
Shareholders will be able to vote (see the “Voting virtually at the Meeting” section of this Notice of
Meeting below) and ask questions at the virtual meeting.
Shareholders are also encouraged to submit questions in advance of the Meeting to the Company.
Questions must be submitted in writing to Simon White, Director of Investor Relations, at
investorrelations@paradigmbiopharma.com at least 48 hours before the AGM.
The Company will also provide Shareholders with the opportunity to ask questions during the
Meeting in respect to the formal items of business as well as general questions in respect to the
Company and its business.
Voting virtually at the Meeting
Shareholders who wish to vote virtually on the day of the AGM can do so by logging into the Automic
shareholder portal.
1. Open your internet browser and go to investor.automic.com.au
2. Login using your username and password. If you do not already have an account, click
“Register” and follow the prompts. Shareholders are encouraged to register prior to the
commencement of the Meeting to avoid delays in accessing the virtual platform.
3. After logging in, a banner will appear at the bottom of your screen when the Meeting is
open for registration. Click “Register”. Alternatively, select Meetings from the left-hand
menu.
4. Click on “Join Meeting” and follow the prompts.
5. When the Chair of the Meeting declares the poll open, select the “Voting” dropdown menu
on the right-hand side of your screen.
6. Select either the “Full” or “Allocate” option to access your electronic voting card.
7. Follow the prompts to record your voting direction for each resolution and click “Submit
votes”. For allocated votes, the number of votes submitted must not exceed your remaining
available units. Important: Votes cannot be amended once submitted.
For further information on the live voting process please see the Registration and Voting Guide at
https://www.automicgroup.com.au/virtual-agms/
It is recommended that Shareholders wishing to attend the Meeting log in from 15 to 30 minutes prior
to the scheduled start time.
5
Voting by proxy
To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in
accordance with the instructions set out on the Proxy Form.
In accordance with section 249L of the Corporations Act, Shareholders are advised that:
• each Shareholder has a right to appoint a proxy;
• the proxy need not be a Shareholder of the Company; and
• a Shareholder who is entitled to cast two or more votes may appoint two proxies and may
specify the proportion or number of votes each proxy is appointed to exercise. If the
Shareholder appoints two proxies and the appointment does not specify the proportion or
number of the member’s votes, then in accordance with section 249X(3) of the
Corporations Act, each proxy may exercise one-half of the votes.
Shareholders and their proxies should be aware that:
• if proxy holders vote, they must cast all directed proxies as directed; and
• any directed proxies which are not voted will automatically default to the Chair, who must
vote the proxies as directed.
Voting in person
To vote in person, attend the Meeting at the time, date and place set out above.
Should you wish to discuss the matters in this Notice please do not hesitate to contact the Company
Secretary on +61 8 6382 1805.
6
E X P L A N A T O R Y S T A T E M E N T
This Explanatory Statement has been prepared to provide information which the Directors believe
to be material to Shareholders in deciding whether or not to pass the Resolutions.
1. FINANCIAL STATEMENTS AND REPORTS
In accordance with the Corporations Act, the business of the Meeting will include receipt
and consideration of the annual financial report of the Company for the financial year
ended 30 June 2025 together with the declaration of the Directors, the Directors’ Report,
the Remuneration Report and the Auditor’s Report.
The Company will not provide a hard copy of the Company’s annual financial report to
Shareholders unless specifically requested to do so. The Company’s annual financial report
is available on its website at www.paradigmbiopharma.com.
2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT
2.1 General
The Corporations Act requires that at a listed company’s annual general meeting, a
resolution that the remuneration report to be adopted must be put to the shareholders.
However, such a resolution is advisory only and does not bind the company or the directors
of the company.
The remuneration report sets out the company’s remuneration arrangements for the
directors and senior management of the company. The remuneration report is part of the
directors’ report contained in the annual financial report of the company for a financial
year.
The chair of the meeting must allow a reasonable opportunity for its shareholders to ask
questions about or make comments on the remuneration report at the annual general
meeting.
2.2 Voting consequences
A company is required to put to its shareholders a resolution proposing the calling of
another meeting of shareholders to consider the appointment of directors of the company
(Spill Resolution) if, at consecutive annual general meetings, at least 25% of the votes cast
on a remuneration report resolution are voted against adoption of the remuneration report
and at the first of those annual general meetings a Spill Resolution was not put to vote. If
required, the Spill Resolution must be put to vote at the second of those annual general
meetings.
If more than 50% of votes cast are in favour of the Spill Resolution, the company must
convene a shareholder meeting (Spill Meeting) within 90 days of the second annual
general meeting.
All of the directors of the company who were in office when the directors' report (as
included in the company’s annual financial report for the most recent financial year) was
approved, other than the managing director of the company, will cease to hold office
immediately before the end of the Spill Meeting but may stand for re-election at the Spill
Meeting.
Following the Spill Meeting those persons whose election or re-election as directors of the
company is approved will be the directors of the company.
2.3 Previous voting results
At the Company’s previous annual general meeting the votes cast against the
remuneration report considered at that annual general meeting were less than 25%.
Accordingly, the Spill Resolution is not relevant for this Meeting.
7
3. RESOLUTION 2 – RE-ELECTION OF A DIRECTOR – AMOS MELTZER
3.1 General
Listing Rule 14.5 provides that an entity which has directors must hold an election of
directors at each annual general meeting.
The Constitution sets out the requirements for determining which Directors are to retire by
rotation at an annual general meeting.
Amos Meltzer, who has held office without re-election since 19 November 2024 in
accordance with the Constitution, will retire in accordance with the Constitution and
being eligible retires by rotation and seeks re-election.
Further information in relation to Mr Meltzer is set out below.
Qualifications,
experience and other
material directorships
Mr Meltzer is a scientist, intellectual property lawyer and former
CEO and VP of business development with over 25 years of
experience in international trade and in commercialising
technologies, principally in the life sciences sector. He has
presided over life science research and product development
projects, clinical trials as well as the commercialisation of life
sciences assets.
Previously, Mr Meltzer served as General Counsel and IP
director at two Nasdaq-listed companies Compugen and
Gilat, as a nonexecutive director of a biotechnology company
Evogene and as VP of Business Development and then CEO of
ASX-listed biopharmaceutical company, Immuron.
Mr Meltzer currently serves as Chief Operating Officer (Aust) of
neuro-medical device company Synchron, chairman of the
Board of Maverick Life Sciences, a company that produces
animal-derived products for medical devices and as a legal
advisor to a number of ASX-listed and private life science
companies
Term of office Mr Meltzer has served as a Director since 9 December 2020.
Independence If re-elected, the Board considers that Mr Meltzer will be an
independent Director.
Board
recommendation
Having received an acknowledgement from Mr Meltzer that he
will have sufficient time to fulfil his responsibilities as a Director
and having reviewed the performance of Mr Meltzer since his
appointment to the Board and the skills, knowledge,
experience and capabilities required by the Board, the
Directors (other than Mr Meltzer) recommend that Shareholders
vote in favour of this Resolution.
3.2 Technical information required by Listing Rule 14.1A
If this Resolution is passed, Mr Meltzer will be re-elected to the Board as an independent
Director.
If this Resolution is not passed, Mr Meltzer will not continue in their role as an independent
Director. The Company may seek nominations or otherwise identify suitably qualified
candidates to join the Company. As an additional consequence, this may detract from
the Board and Company’s ability to execute on its strategic vision.
4. RESOLUTION 3 – APPROVAL TO ISSUE TRANCHE 3 CONVERTIBLE NOTES TO OBSIDIAN GLOBAL
GP, LLC
4.1 Background
As announced on 1 July 2025, the Company has entered into a convertible securities and
share placement agreement (Convertible Securities Agreement) and secured
commitments for up to US$27,000,000 through the issuance of convertible notes
8
(Convertible Notes) to Obsidian Global GP, LLC (Obsidian) comprising an initial drawdown
of US$7,000,000 plus any subsequent drawdowns as agreed between the Company and
Obsidian and subject to shareholder approval.
In accordance with the Convertible Securities Agreement, the first drawdown of
US$7,000,000 (First Purchase) was provided by Obsidian to the Company in exchange for
7,000,000 Convertible Notes (each with a face value of US$1.09) (Tranche 1 Convertible
Notes) which were issued on 7 July 2025.
As of the date of this Notice, the Company has received conversion notices from Obisidian
for US$4,251,000 worth of Tranche 1 Convertible Notes, and has issued Shares upon
conversion of these Tranche 1 Convertible Notes as follows:
(a) On 25 August 2025, the Company issued 6,066,476 Shares upon conversion of
1,000,000 Tranche 1 Convertible Notes (with a face value of US$1,090,000); and
(b) On 9 September 2025, the Company issued 8,300,335 Shares upon conversion of
1,200,000 Tranche 1 Convertible Notes (with a face value of US$1,308,000); and
(c) On 8 October 2025, the Company issued 11,714,207 Shares upon conversion of
1,700,000 Tranche 1 Convertible Notes (with a face value of US$1,853,000).
Subject to Shareholder approval and mutual agreement, the Company may drawdown
an additional US$5,000,000 or such other amount as agreed up to US$20,000,000
(Subsequent Purchases) in exchange for the issue of Convertible Notes (each with a face
value of US$1.09).
Pursuant to the Convertible Securities Agreement, Subsequent Purchases may be made
90 days after the First Purchase, or at such other times as Obsidian and the Company may
agree, provided that no Subsequent Purchase can occur except at the request of the
Company and no Subsequent Purchase can occur after the date which is 30 months after
the execution date of the Convertible Securities Agreement.
The Company sought and obtained Shareholder approval at the extraordinary general
meeting held on 23 September 2025 to draw down an additional US$10,000,000,
comprising:
(a) a US$5,000,000 tranche (Tranche 2) for 5,000,000 Convertible Notes
(Tranche 2 Convertible Notes); and
(b) approximately 90 days after the issue of the Tranche 2 Convertible Notes, an
additional US$5,000,000 tranche (Tranche 3) for 5,000,000 Convertible Notes
(Tranche 3 Convertible Notes),
(collectively, the Subsequent Convertible Notes).
The Company has not yet drawn down on funds available under Tranche 2 of the
Convertible Note facility as at the date of this Notice. Under the terms of the Convertible
Securities Agreement, any draw down of funds under Tranche 3 is contingent on the prior
draw down of the US$5,000,000 worth of funds available under Tranche 2.
The Company proposes to renew the Shareholder approval for the proposed issue of the
Tranche 3 Convertible Notes (being, the subject of this Resolution 3) to provide additional
flexibility and allow further time for the Company to effect drawdowns under Tranche 2
and Tranche 3, which together represent a portion of the Subsequent Purchases, in
accordance with the terms of the Convertible Securities Agreement.
Additionally, in consideration for Obsidian entering into the Convertible Securities
Agreement, the Company agreed to issue Obsidian a total of 8,000,000 Shares
(Placement Shares) which were issued on 2 July 2025.
The terms and conditions of the Convertible Securities Agreement are set out in
Schedule 1. For further information in relation to the Convertible Securities Agreement,
please refer to the Company’s announcement dated 1 July 2025 and cleansing notice
dated 7 July 2025.
9
4.2 Use of funds
The Company intends to apply the funds raised under the Convertible Securities
Agreement to immediate working capital to support site activation and clinical trial
operations. The balance of the facility is available at the Company’s discretion, offering
operational flexibility and strategic control over future funding needs.
4.3 Listing Rule 6.1
Listing Rule 6.1 requires that any convertible securities issued by a company are issued on
terms that are considered appropriate and equitable. In determining whether the
convertible securities are appropriate and equitable, the terms and conditions of the
convertible securities must be fair to both new and existing shareholders of the company.
If the convertible securities appear to be favourable to the holder of the convertible
securities, the company is required to explain the circumstances underpinning the issue of
the convertible securities.
The Company provides the following information for the purposes of section 4 of ASX
Compliance Update No 05/20, and ASX Compliance Update No 05/23:
(a) the Company has negotiated the Convertible Securities Agreement at arm’s
length with a sophisticated and professional investor who is an independent third
party to the Company;
(b) the Company considers that the issue of the Convertible Notes is an appropriate
and commercial solution to provide working capital to ensure the Company is
fully funded through several key clinical milestones noted above;
(c) prior to entering into the Convertible Securities Agreement, the Company
considered other available fund-raising options, such as a traditional equity
raising and other types of equity linked debt instruments, to meet the Company’s
funding requirements. The Company was of the view that the other options
available were not in the best interests of Shareholders of the Company taking
into account the flexibility and low cost of capital offered by the Convertible
Securities Agreement relative to the other options; and
(d) the Company agreed to both enter into a general security agreement and to
issue the Placement Shares as ‘collateral shares’ to Obsidian. The reason why the
Placement Shares were issued in addition to the grant of security under the
general security agreement is that the Placement Shares are intended to be used
to offset any future Shares issued to Obsidian at its discretion.
The Company confirms that it sought legal advice from Steinepreis Paganin regarding the
suitability of the terms of the Convertible Notes and was advised that the Convertible Notes
were market standard and do not contain any of the features noted in section 5.9 of ASX
Guidance Note 21, based on the reasons set out below:
(a) conversion of the Convertible Notes is at a price based on the market price for
Shares and not some other variable;
(b) the Convertible Notes convert into ordinary shares in the Company and not into
other convertible securities; and
(c) there are other convertible notes on similar terms in the marketplace.
4.4 General
As set out in Section 4.1 above, the Company seeks Shareholder approval to issue
5,000,000 Tranche 3 Convertible Notes to Obsidian, with the subsequent entitlement to
convert into Shares.
A summary of Listing Rule 7.1 is set out in Section 4.1 above.
The proposed issue falls within exception 17 of Listing Rule 7.2. It therefore requires the
approval of Shareholders under Listing Rule 7.1.
Pursuant to the Convertible Securities Agreement, the number Shares issued upon a
conversion of the Subsequent Convertible Notes (Subsequent Convertible Note Shares) will
be determined by the following formula:
10
Number of Subsequent Convertible Note Shares = Face Value / Conversion Price
Where:
Conversion Price means the Fixed Conversion Price, or the Variable Conversion
Price, or (only where permitted under the Convertible Securities Agreement), the
lesser of:
(a) 85% of the lowest daily VWAP during the 10 Actual Trading Days prior to
the conversion notice date; and
(b) the Fixed Conversion Price,
as relevant in respect of a conversion.
Fixed Conversion Price means 150% of the 5-day VWAP for the 5 Actual Trading
Days immediately prior to the relevant Purchase Date.
Variable Conversion Price means the lesser of:
(a) 94% of the average of the lowest 5 daily VWAPs during the 20 Actual
Trading Days prior to the conversion notice date rounded down to the
lowest A$0.01; and
(b) the Fixed Conversion Price.
Exchange Rate means, in respect of the conversion of one currency into another
currency on a particular day, the spot rate of exchange displayed for that day
on the Res
Share your feedback
Discover